We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where ...

Brookline Capital Management issued their Q3 2025 earnings estimates for shares of CRISPR Therapeutics in a report released ...

CRISPR Therapeutics (CRSP, Financials) stock rose 16.4% to $50.60 as of 10:10 a.m. GMT-5 on Friday, following an analyst ...

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from In-Line to Outperform. Analyst Price Forecast Suggests 90.46% Upside As ...

Citi analysts adjusted their outlook on CRISPR Therapeutics (NASDAQ:CRSP) stock, reducing the price target to $82 from $89 while maintaining a Buy rating. The stock, which has shown significant ...

CRISPR Therapeutics (CRSP) shares jump after Evercore ISI upgraded the stock to Outperform from In Line. Julie Hyman and Josh ...

CFO Beth Jantzen reported total revenues of $1.2 million for Q1 2025, a year-over-year increase driven by higher product revenue from DNA Tagging and increased isotopic testing services. Operating ...

Applied DNA Sciences, Inc. (NASDAQ: APDN) Q1 2025 Earnings Call Transcript February 13, 2025 Applied DNA Sciences, Inc. misses on earnings expectations. Reported EPS is $-0.56 EPS, expectations were $ ...

Sequencing bacterial genomes allows scientists to study bacterial diversity, immunity, and the human microbiome, but it ...